Fax: (713) 794-4901
The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma†
Article first published online: 27 JUL 2006
Copyright © 2006 American Cancer Society
Volume 107, Issue 5, pages 967–974, 1 September 2006
How to Cite
Malaisrie, S. C., Hofstetter, W. L., Correa, A. M., Ajani, J. A., Komaki, R. R., Rice, D. C., Vaporciyan, A. A., Walsh, G. L., Roth, J. A., Wu, T. T. and Swisher, S. G. (2006), The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer, 107: 967–974. doi: 10.1002/cncr.22077
Presented at the Western Thoracic Surgical Association, Victoria, Canada, June 22–25, 2005.
- Issue published online: 21 AUG 2006
- Article first published online: 27 JUL 2006
- Manuscript Accepted: 12 APR 2006
- Manuscript Revised: 2 APR 2006
- Manuscript Received: 17 NOV 2005
- esophageal cancer;
- induction therapy;
- tumor response
Tumor viability assessed by pathologic analysis of resected specimens in patients with preoperatively treated esophageal adenocarcinoma (EAC) is a prognostic indicator. The feasibility of induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) and surgery for patients with locoregionally advanced EAC has been demonstrated. In this study, the authors evaluated the efficacy of CCRT compared with traditional concurrent chemoradiotherapy (CRT).
The authors retrospectively reviewed 247 consecutive patients with EAC who presented for planned surgery after treatment with either CCRT or CRT from January 1997 through August 2003. Patient demographics, comorbidities, and tumor characteristics were analyzed. Pathologic tumor response, overall survival, and disease-free survival were assessed according to treatment.
One hundred seventeen patients received CCRT, and 130 patients received CRT before planned surgical resection. CCRT resulted in a 64% tumor response rate compared with a 51% tumor response rate in the CRT group (odds ratio, 1.73; P = .035). In the CCRT group, the median overall survival was 55 months, and the 3-year overall survival rate was 59%; in the CRT group, the median overall survival was 25 months, and the 3-year overall survival rate was 41% (hazard ratio [HR], 0.69; P = .041). In the CCRT group, the median disease-free survival was 43 months, and the 3-year disease-free survival rate was 54%; in the CRT group, the median disease-free survival was 18 months, and the 3-year disease-free survival rate was 36% (HR, 0.72; P = .047). Subset analysis of patients with clinical Stage III/IVA disease showed a median overall survival of 51 months with a 3-year overall survival rate of 58% in the CCRT group and a median overall survival of 20 months with a 3-year overall survival rate of 28% in the CRT group (HR, 0.57; P = .019).
In patients with EAC, CCRT improved tumor response significantly compared with traditional CRT alone. Overall survival and disease-free survival were increased in patients who received CCRT, especially in the subset of patients who had more advanced disease. Cancer 2006. © 2006 American Cancer Society.